The activity of Catechol-O-Methyltransferase in parkinsonian patients with ″on-off fluctuations″

Journal of Neural Transmission

Volumn 107, Issue 1, 2000, Pages 105-111

  Woitalla, D ^a   Karwasz, R ^a   Muller Th ^a   Przuntek, H ^a   Kuhn, W ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

COMT; Motor fluctuations; Parkinson disease

Indexed keywords

CATECHOL METHYLTRANSFERASE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0033979446     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050009     Document Type: Article

References (28)

1. Axelrod J, Tomchick R (1958) Enzymatic o-methylation of epinephrine and other catechols. J Biol Chem 233: 702-705
2. Bade P, Christ W, Rakow D, Coper H (1976) Comparison of Catechol-O-Methyltransferase from rat brain, erythrocytes and liver. Life Sci 19: 1833-1844
3. Barbeau A (1974) The clinical physiology of side effects in long-term l-dopa therapy. Adv Neurol 5: 347-365
4. Boudikova B, Szumlanski B, Maidak B, Weinshilboum R (1990) Human liver Catechol-O-Methyltransferase pharmacogenetics. Clin Pharmacol Ther 48: 381-389
5. Cedarbaum JM, Kutt H, McDowell FH (1988) Clinical significance of the relationsship between o-methyldopa levels and levodopa intake. Neurology 38: 533-536
6. Chase TN, Fabbrini G, Juncos JL, Mouradian MM (1990) Motor response complications with chronic levodopa therapy. Adv Neurol 53: 377-381
7. Da Prada M (1990) Peripheral decarboxylase inhibition: a biochemical comparison between benserazide and carbidopa. In: Birkmayer W, Rinne UK, Worm-Petersen J, Dupont E, Schwarz W (eds) Parkinson's disease. Actual problems and management. Editiones Roche, Basel, pp 25-38
8. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN (1987) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21(4): 370-376
9. Fahn S (1974) "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431-441
10. Guldberg HC, Marsden CA (1975) Catechol-O-Methyltransferase: pharmacological aspects and physiological role. Pharmacol Rev 27(2): 135-200
11. Hoda F, Nicholl D, Benett P, Arranz M, Aitchison KJ, Al-Chalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR, Collier DA (1996) No association between Parkinson's disease and low-activity alleles of Catechol-O-Methyltransferase. Biochem Biophys Res Commun 228: 780-784
12. Kastner A, Anglade P, Bounaix C, Damier P, Javoy-Agid F, Bromet N, Agid Y, Hirsch EC (1994) Immunhistochemical study of Catechol-O-Methyltransferase in the human mesostriatal system. Neurosci 62: 449-457
13. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in parkinsonian's disease. Lancet 12: 345-349
14. Mouradian MM, Chase TN (1988) Central mechanisms and levadopa response fluctuations in Parkinsons disease. Clin Neuropharm 11(4): 378-385
15. Muenter MD, Sharpless NS, Tyce GM (1972) Plasma 3-O-methyldopa in l-dopa therapy of Parkinson's disease. Mayo Clin Proc 47: 389-395
16. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21(6): 584-588
17. Obeso JA, Luquin MR, Vaamonde J, Lera G, Rodriguez M, Grandas F, Martinez-Lage JM (1991) Central pathophysiology of levodopa complications in Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R (eds) International Workshop Berlin on Parkinson's disease. Medicom Europe, Bussum, pp 185-192
18. Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levadopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662: 69-74
19. Quinn NP, Marion MH, Marsden CD (1987) Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 Patients with Parkinson's disease and "on-off" fluctuations. Eur Neurol 27 [Suppl]: 105-113
20. Reches A, Fahn S (1984) Catechol-O-Methyltransferase and Parkinson's disease. Adv Neurol 40: 171-179
21. Reilly DK, Rivera-Calimlim L, Van Dyke D (1980) Catechol-O-Methyltransferase activity: a determinant of levadopa response. Clin Pharmacol Ther 28: 278-286
22. Rivera-Calimlim L, Reilly DK (1984) Difference in erythrocyte Catechol-O-Methyltransferase activity between orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 28: 278-286
23. Rivera-Calimlim L, Tandon D, Anderson F, Joynt R (1977) The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Arch Neurol 34: 228-232
24. Sage JI, Mark MH (1994) Basic mechanisms of motor fluctuations. Neurology 44 [Suppl 6]: 10-14
25. Stocchi F, Bonomartini A, Vacca L, Ruggieri S (1996) Mottor fluctuations in levodopa treatment: clinical pharmacology. Eur Neurol 36 [Suppl 1]: 38-42
26. Tenhunen J, Salminen M, Jalanko A, Ukkonen S, Ulmanen I (1993) Genetic polymorhism of Catechol-O-Methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland. DNA and Cell Biol 12: 253-263
27. Weinshilboum R, Dunette J (1981) Thermal stability and the biochemical genetics of erythrocyte Catechol-O-Methyltransferase and plasma dopamine-beta-hydroxylase. Clin Genet 19: 426-437
28. Youdim MBH (1990) Inhibitors of dopamine inactivating systems as antiparkinsonian drugs. Adv Neurol 53: 483-488